At Glysantis, we are leveraging the NanoDendrix™ glycogen nanoparticle platform to develop novel cancer therapeutics. We are currently pursuing two parallel strategies, at different phases of discovery and development 

  1. Innate immune-boosting
    Activating the innate immune response in the tumor microenvironment with a TLR-targeting nanoparticle-polymer complex. Potential to enhance standard-of-care chemo- and immunotherapies in solid tumors. Lead candidate GLY-100 at the pre-clinical stage.

  2. Nanoparticle-drug conjugates
    Cytotoxin-loaded nanoparticles armed with targeting ligands that recognize tumor-overexpressed receptors. Discovery stage candidate GLY-200.